We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The epidemiology, symptoms, diagnosis and management of monkeypox virus infections.
Pfizer Limited is recalling all distributed batches of Oxbryta 500 mg Tablets. Pfizer Limited has informed the MHRA that the product is being withdrawn due to emerging data from clinical trials and registry-based studies.
This page provides an overview of countries reporting clade I mpox cases (historic or current), indicating where there may be a risk of clade I mpox exposure.
This release has been published in response to confirmed cases of clade Ib mpox in the UK. Whilst numbers remain low updates will be released on an ad-hoc basis.
The UK Health Security Agency (UKHSA) confirms additional cases of Clade Ib mpox.
Follow-up advice for contacts of a clade I mpox case.
Additional vaccines will help ensure the UK can protect those that may be at higher risk of coming into contact with mpox.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).